Augmented Depression Therapy (ADepT) Case Series

NCT07733310 | Not Yet Recruiting

• 1 other identifier: 20251473
• Study Type: interventional
• Target: 40
• Locations: 1 country
• Sites: 1

Brief Summary

This research study plans to examine the use of Augmented Depression Therapy (ADepT) in order to evaluate what patients think about ADepT and how well it works. ADepT is a type of therapy that builds wellbeing and is being provided to you as standard of care. ADepT treatment consists of 15 therapy sessions (typically provided weekly) with each session lasting around 60 minutes. Following these sessions, you can receive five optional booster sessions over the next 12 months with each of these lasting around 60 minutes. Ultimately, the timing and duration of these sessions will be determined between you and your provider and scheduled accordingly. As part of this study you will be randomized (randomly assigned) to different research assessment lengths before the start of treatment and then will complete assessments for the 12 months following the end of the weekly portion of ADepT treatment. The length of your participation will be between 70 weeks to 82 weeks.

Conditions

Depression / Major Depressive Disorder

Keywords

Depression; Major Depressive Disorder; Major Depressive Episode

Outcome Measures

Primary Outcomes (3)

• Acceptability

  Patient ratings of treatment acceptability

  From enrollment to the end of treatment at 82 weeks

• Attrition

  Patient attendance records

  From enrollment to the end of treatment at 82 weeks.

• Adverse Events

  Self-reported adverse events

  From enrollment to the end of treatment at 82 weeks.

Secondary Outcomes (3)

• Montgomery-Asberg Depression Rating Scale (MADRS)

  From enrollment to the end of treatment at 82 weeks.

• Patient Health Questionnaire - 9 Item Version (PHQ-9)

  From enrollment to the end of treatment at 82 weeks.

• Warwick-Edinburgh Mental Wellbeing Scale (WEMWBS)

  From enrollment to the end of treatment at 82 weeks.

Study Arms (6)

3 week baseline + ADepT

EXPERIMENTAL

Baseline assessments will be made weekly for 3 weeks, followed by a standard course of ADepT.

Behavioral: Augmented Depression Therapy (ADepT)

4 week baseline + ADepT

EXPERIMENTAL

Baseline assessments will be made weekly for 4 weeks, followed by a standard course of ADepT.

Behavioral: Augmented Depression Therapy (ADepT)

5 week baseline + ADepT

EXPERIMENTAL

Baseline assessments will be made weekly for 5 weeks, followed by a standard course of ADepT.

Behavioral: Augmented Depression Therapy (ADepT)

6 week baseline + ADepT

EXPERIMENTAL

Baseline assessments will be made weekly for 6 weeks, followed by a standard course of ADepT.

Behavioral: Augmented Depression Therapy (ADepT)

7 week baseline + ADepT

EXPERIMENTAL

Baseline assessments will be made weekly for 7 weeks, followed by a standard course of ADepT.

Behavioral: Augmented Depression Therapy (ADepT)

8 week baseline + ADepT

EXPERIMENTAL

Baseline assessments will be made weekly for 8 weeks, followed by a standard course of ADepT.

Behavioral: Augmented Depression Therapy (ADepT)

Interventions

Augmented Depression Therapy (ADepT) BEHAVIORAL

ADepT is a solution-focused behavioral health intervention that blends techniques from cognitive, behavioral, and acceptance-based treatments to help patients manage symptoms of depression and increase wellbeing. It consists of 15 acute treatment sessions and up to 5 booster sessions.

3 week baseline + ADepT; 4 week baseline + ADepT; 5 week baseline + ADepT; 6 week baseline + ADepT; 7 week baseline + ADepT; 8 week baseline + ADepT

Eligibility Criteria

• Age: 18 Years - 65 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Aged 18 -65
• Currently experiencing a major depressive episode based on the Quick Structured Clinical Interview for DSM-5 Disorders (QuickSCID-5; First \& Williams, 2021)
• Scoring \> 10 on the PHQ-9
• Have sufficient knowledge of written and spoken English to provide consent and utilize therapy resources and take assessment measures throughout the protocol without the assistance of a translator.

You may not qualify if:

• Diagnosis of a psychotic or bipolar disorder
• History of learning disabilities or organic brain change (e.g., from injury or from neurological disorders)
• Active alcohol or substance use disorder or level of use that would interfere with ability to engage in ADepT treatment
• Current marked risk to self (self-harm or suicidal ideation) that cannot be managed safely within the ADepT treatment frame
• Patients cannot be enrolled while they are currently receiving psychotherapy from a different provider in line with current clinic policy and APA ethical guidelines. The possibility of switching providers/treatments will be addressed following established departmental policies and procedures, transcranial magnetic stimulation, ketamine, esketamine, or electroconvulsive therapy. Patients receiving a stable dose of an antidepressant agent will be considered eligible.
• Presence of another psychiatric disorder judged to be primary

Sponsors & Collaborators

• Ohio State University: lead

Study Sites (1)

The Ohio State University Wexner Medical Center

Columbus, Ohio, 43214, United States

Location

MeSH Terms

Conditions

Depression; Depressive Disorder, Major

Condition Hierarchy (Ancestors)

Behavioral Symptoms; Behavior; Depressive Disorder; Mood Disorders; Mental Disorders

Central Study Contacts

Jay Fournier, Ph.D.

CONTACT

614-814-6485; Jay.Fournier@osumc.edu

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Principal Investigator

Model Details: Randomized multiple baseline case series design

Study Record Dates

• First Submitted: July 23, 2026
• First Posted: July 29, 2026
• Study Start: August 1, 2026
• Primary Completion (Estimated): August 31, 2028
• Study Completion (Estimated): December 31, 2028
• Last Updated: July 29, 2026

Record last verified: 2026-07

Data Sharing

• IPD Sharing: Will share

Locations

US (1)